Tencent invested $15.3m in gene therapy-focused research services provider Obio Technology in its third funding round of 2020.
Internet group Tencent has supplied RMB100m ($15.3m) in series C-plus funding for China-based contract research organisation Obio Technology, DealStreetAsia reported yesterday.
Founded in 2013, Obio undertakes biochemical research outsourced by clients such as drug developer developers, with a focus on gene therapy-led projects.
Tencent’s investment comes three months after Obio pulled in $44.2m in a series C round that included private equity firm Loyal Valley Capital and 5Y Capital, the venture capital firm formerly known as Morningside Group.
The September…
